Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2023). On theSindex it has a DataRank of 0.182. It has been cited 2 times, with 2 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.165
From this paper's citation signal
Citation Network Contribution
0.0170
From 2 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 2 citers.
National Institutes of Health
Grant: P01 CA030206
National Institutes of Health
Grant: P30 CA033572
FWCI
0.35
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals